Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 5
2013 4
2014 4
2015 3
2016 4
2017 13
2018 8
2019 7
2020 13
2021 9
2022 8
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. Among authors: kawakita d. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
Hirai H, Nakaguro M, Tada Y, Saigusa N, Kawakita D, Honma Y, Kano S, Tsukahara K, Ozawa H, Okada T, Okami K, Yamazaki K, Sato Y, Urano M, Kajiwara M, Utsumi Y, Shimura T, Fushimi C, Shimizu A, Kondo T, Imanishi Y, Sakai A, Sato Y, Togashi T, Hanazawa T, Matsuki T, Yamazaki K, Nagao T. Hirai H, et al. Among authors: kawakita d. Virchows Arch. 2023 Sep;483(3):367-379. doi: 10.1007/s00428-023-03598-3. Epub 2023 Jul 19. Virchows Arch. 2023. PMID: 37464232
Alcohol and head and neck cancer.
Kawakita D, Matsuo K. Kawakita D, et al. Cancer Metastasis Rev. 2017 Sep;36(3):425-434. doi: 10.1007/s10555-017-9690-0. Cancer Metastasis Rev. 2017. PMID: 28815324 Review.
Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis.
Shimoda H, Teshima M, Murase T, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu KI, Inagaki H. Shimoda H, et al. Among authors: kawakita d. Oral Oncol. 2023 Oct;145:106491. doi: 10.1016/j.oraloncology.2023.106491. Epub 2023 Jul 22. Oral Oncol. 2023. PMID: 37487445
The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma.
Ueda K, Murase T, Kawakita D, Nagao T, Kusafuka K, Nakaguro M, Urano M, Yamamoto H, Taguchi KI, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu KI, Inagaki H. Ueda K, et al. Among authors: kawakita d. Mod Pathol. 2023 Oct;36(10):100274. doi: 10.1016/j.modpat.2023.100274. Epub 2023 Jul 7. Mod Pathol. 2023. PMID: 37423587
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Kawakita D, et al. Ther Adv Med Oncol. 2022 Sep 6;14:17588359221119538. doi: 10.1177/17588359221119538. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090801 Free PMC article.
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, Mano H. Kohsaka S, et al. Among authors: kawakita d. NPJ Precis Oncol. 2022 Nov 4;6(1):82. doi: 10.1038/s41698-022-00324-1. NPJ Precis Oncol. 2022. PMID: 36333410 Free PMC article.
Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer.
Homma A, Ando M, Hanai N, Harada H, Honma Y, Kanda T, Kano S, Kawakita D, Kiyota N, Kizawa Y, Nakagawa M, Ogawa T, Shinomiya H, Shinozaki T, Suzuki M, Tsuji T, Yasuda K, Zenda S, Kodaira T, Kirita T, Nibu KI. Homma A, et al. Among authors: kawakita d. Auris Nasus Larynx. 2024 Feb;51(1):174-188. doi: 10.1016/j.anl.2023.07.003. Epub 2023 Jul 21. Auris Nasus Larynx. 2024. PMID: 37482431 Review.
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: kawakita d. Cancer Med. 2023 Dec;12(24):21666-21679. doi: 10.1002/cam4.6724. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37986680 Free PMC article.
81 results